The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

What happened: Investor excitement around Moderna's experimental cancer treatment is cooling after the Phase 3 data, according to MarketWatch. Expectations heading into the data had been "incredibly high." Why it matters: The report frames the shift as a cooling of sentiment around the Phase 3 results for the drugmaker's experimental cancer vaccine, suggesting the data did not sustain the elevated expectations investors held beforehand.

Investor excitement around Moderna's experimental cancer treatment is cooling after the Phase 3 data, according to MarketWatch. Expectations heading into the data had been "incredibly high."

The report frames the shift as a cooling of sentiment around the Phase 3 results for the drugmaker's experimental cancer vaccine, suggesting the data did not sustain the elevated expectations investors held beforehand.